Digital Pathology Market Pioneers Towards a Substantial US$ 24,961.8 Million by 2033

The digital pathology market share is projected to be worth US$ 7,035.8 million in 2023. It is likely that the market will reach US$ 24,961.8 million by 2033. Furthermore, the industry is expected to increase at a compound annual growth rate (CAGR) of 13.5% between 2023 and 2033.

The increased use of advanced analytics in pharma and medical testing are two key factors boosting the digital pathology market’s adoption. Healthcare financing organizations and government bodies are implementing analytics through claim management and fraud prevention, which is fueling the market growth.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-124

Surge in R&D in Digital Pathology to Augment Sales in Forthcoming Years

In recent years, the digital pathology industry has increased investments in biosimilar research and development initiatives, primarily for cancer treatment and Covid-19 treatment, which have substantially fuelled the market expansion.

Contract Research Organizations (CROs), in-vitro diagnostics (IVD) laboratories, clinical laboratories, and regulatory consultants are being assigned biosimilar development responsibilities by pharmaceutical corporations. These enterprises are developing in order to provide more cost-efficient solutions to their customers, requiring the use of digital pathology instruments to diagnose, research, and design effective healthcare solutions.

Cancer diagnostic Opens New Avenues for Digital Pathology Companies

Due to the sheer increasing occurrence of cancer, there is an increase in spending on digital pathology equipment. Complications arising from late cancer diagnosis, particularly in the case of blood cancer and lung cancer, necessitate the use of significant capital resources during therapy and diagnosis. The success of digital pathology in research is driving demand for these systems in the cancer research industry. This is also encouraging government investors to invest in digital pathology systems for clinical diagnosis. A significant amount of money is spent on cancer diagnosis and therapy monitoring. This explains why digital pathology solutions are in high demand.

Competitive Landscape

• Danaher Corporation
• F. Hoffmann-La Roche AG
• Huron Technologies International Inc.
• Koninklijke Philips N.V.
• Olympus Corporation
• Hamamatsu Photonics K.K.
• Carl Zeiss AG
• Nikon Corporation
• 3DHISTECH Ltd.
• Hologic Inc.
• PerkinElmer, Inc.
• Visiopharm
• OptraSCAN, Inc.
• Inspirata, Inc.
• Sectra AB

Unlock exclusive insights with our expert analysts:
https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-124

Some of the recent developments in digital pathology market are as follows:

• In May 2021, Leica Biosystems joined the European Society for Digital and Integrative Pathology (ESDIP) to assist pathology labs in developing laboratories in accordance with modern digital pathology instruments.
• In March 2021, Roche inked a comprehensive merger agreement with GenMark Diagnostics to broaden its product and distribution channel for European consumers.

Request Report Methodology:https://www.futuremarketinsights.com/request-report-methodology/rep-gb-124

Key Segments:

Digital Pathology by Product Type:

• Digital Pathology Equipment
• Whole Slide Scanners
• Brightfield Slide Scanners
• Fluorescence Slide Scanners
• Combination Slide Scanners
• Clinical Microscope
• Tissue Microarrays
• Digital Pathology Software
• Image Viewing and Analysis Software
• On-premise
• Cloud-based
• Digital Pathology Information Systems
• On-premise
• Cloud-based
• Digital Pathology Services
• Installation and Integration Services
• Consulting Services
• Maintenance and Validation Services

Digital Pathology by Application:

• Clinical Pathology
• Molecular Diagnostics
• Basic & Applied Research
• Drug Development
• Others

Digital Pathology by End User:

• Hospitals
• Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Forensic Laboratories
• Research Institutes
• Contract Research Organizations (CROs)
• Clinics

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube